CNS lymphoma · 12 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
High-dose Cytarabine monotherapy (HiDAC) Variant #01 | — | R 26 364 | — | ~5.2 mo | — | — | — | 1 |
Bu/TT Variant #01 Partial | — | R 26 139 | — | — | — | — | — | — |
Cytarabine and Etoposide (CYVE) Variant #06 | — | R 11 761 | — | — | ~9.2 mo | — | — | — |
Temozolomide monotherapy Variant #13 | — | R 8 153 | 28d | ~4.0 mo | ~16.3 mo | ~5 | ~R 40 764 PFS proxy · indirect | 10 |
BEAM Variant #01 Partial | — | R 4 294 | — | — | — | — | — | — |
Lomustine, Methotrexate, Procarbazine N/A - intrathecal component | — | R 18 | 45d | — | — | — | — | — |
Bu/TT/Cy N/A - secondary systemic drug | — | R 0 | — | — | — | — | — | — |
BCNU/TT Variant #01 Partial | — | — | — | — | — | — | — | — |
Observation Partial | — | — | — | — | 37.1 mo | — | — | 1 |
Methotrexate monotherapy Partial | — | — | — | ~2.6 mo | ~6.7 mo | — | — | 10 |
Procarbazine monotherapy Variant #01 Partial | — | — | 28d | — | — | — | — | — |
Whole brain irradiation N/A - radiation Partial | — | — | 21d | — | — | — | — | 1 |
12 of 12 regimens shown